NZ321626A - 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h)-one derivatives for use as 5-ht4 or h3 receptor ligands - Google Patents

5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h)-one derivatives for use as 5-ht4 or h3 receptor ligands

Info

Publication number
NZ321626A
NZ321626A NZ321626A NZ32162696A NZ321626A NZ 321626 A NZ321626 A NZ 321626A NZ 321626 A NZ321626 A NZ 321626A NZ 32162696 A NZ32162696 A NZ 32162696A NZ 321626 A NZ321626 A NZ 321626A
Authority
NZ
New Zealand
Prior art keywords
oxadiazol
piperidin
phenyl
derivatives
receptor ligands
Prior art date
Application number
NZ321626A
Other languages
English (en)
Inventor
Samir Jegham
Alistair Lochead
Frederic Galli
Alain Nedelec
Axelle Solignac
Cruz Laurence De
Original Assignee
Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9513253A external-priority patent/FR2741070B1/fr
Priority claimed from FR9513252A external-priority patent/FR2741069B1/fr
Priority claimed from FR9602663A external-priority patent/FR2745574B1/fr
Application filed by Synthelabo filed Critical Synthelabo
Publication of NZ321626A publication Critical patent/NZ321626A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
NZ321626A 1995-11-09 1996-11-05 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h)-one derivatives for use as 5-ht4 or h3 receptor ligands NZ321626A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR9513253A FR2741070B1 (fr) 1995-11-09 1995-11-09 Derives de 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h) -one, leur preparation et leur application en therapeutique
FR9513252A FR2741069B1 (fr) 1995-11-09 1995-11-09 Derives de 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h) -one, leur preparation et leur application en therapeutique
FR9602663A FR2745574B1 (fr) 1996-03-04 1996-03-04 Derives de 5-phenyl-3-(piperidin-4-yl)-1, 3, 4-oxadiazol-2 (3h)-one, leur preparation et leur application en therapeutique
PCT/FR1996/001730 WO1997017345A1 (fr) 1995-11-09 1996-11-05 Derives de 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h)-one, utiles comme ligands des recepteurs 5-ht4 ou h¿3?

Publications (1)

Publication Number Publication Date
NZ321626A true NZ321626A (en) 1998-10-28

Family

ID=27253120

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ321626A NZ321626A (en) 1995-11-09 1996-11-05 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h)-one derivatives for use as 5-ht4 or h3 receptor ligands

Country Status (29)

Country Link
US (1) US5929089A (enExample)
EP (1) EP0863897B1 (enExample)
JP (1) JP4263240B2 (enExample)
CN (1) CN1077891C (enExample)
AR (1) AR004708A1 (enExample)
AT (1) ATE181328T1 (enExample)
AU (1) AU707325B2 (enExample)
BG (1) BG63463B1 (enExample)
BR (1) BR9611311A (enExample)
CA (1) CA2236357C (enExample)
CO (1) CO4770968A1 (enExample)
CZ (1) CZ287268B6 (enExample)
DE (1) DE69602970T2 (enExample)
EE (1) EE03487B1 (enExample)
ES (1) ES2135934T3 (enExample)
GR (1) GR3030823T3 (enExample)
HU (1) HUP0001168A3 (enExample)
IL (1) IL124364A (enExample)
MX (1) MX9803696A (enExample)
NO (1) NO309606B1 (enExample)
NZ (1) NZ321626A (enExample)
PL (1) PL186204B1 (enExample)
RU (1) RU2167160C2 (enExample)
SI (1) SI0863897T1 (enExample)
SK (1) SK282335B6 (enExample)
TR (1) TR199800827T2 (enExample)
TW (1) TW371303B (enExample)
UA (1) UA50748C2 (enExample)
WO (1) WO1997017345A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW467902B (en) * 1996-07-31 2001-12-11 Bristol Myers Squibb Co Diphenyl heterocycles as potassium channel modulators
FR2762316B1 (fr) * 1997-04-18 1999-12-17 Sanofi Synthelabo Derives de 5-aryl-3-(8-azabicyclo[3.2.1] octan-3-yl)-1,3,4- oxadiazol-2(3h)-one, leur preparation et leur application en therapeutique
JP2002504896A (ja) * 1997-05-06 2002-02-12 サノフィ−サンテラボ ５−フェニル−１，３，４−オキサジアゾール−２（３ｈ）−オン誘導体およびそれらの５−ｈｔ４リガンドとしての使用
FR2763068B1 (fr) * 1997-05-06 1999-06-04 Synthelabo Derives de 3-(pyrrolidin-3-yl)-1,3,4-oxadiazol-2(3h)-one, leur preparation et leur application en therapeutique
GB9715816D0 (en) * 1997-07-25 1997-10-01 Black James Foundation Histamine H receptor ligands
US6960579B1 (en) 1998-05-19 2005-11-01 Alcon Manufacturing, Ltd. Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders
EP1112106B1 (en) 1998-09-18 2005-11-23 Alcon Manufacturing Ltd. Serotonergic 5ht2 agonists for treating glaucoma
JP2002542287A (ja) * 1999-04-28 2002-12-10 レスピラトリウス アクチボラゲット 医 薬
CN1355698A (zh) * 1999-06-15 2002-06-26 呼吸器有限公司 可用作治疗有关支气管收缩的机能障碍的药物的化合物
PT1313721E (pt) 2000-08-08 2006-06-30 Ortho Mcneil Pharm Inc Ariloxialquilaminas nao imidazoles como ligandos de receptor h3
AU8112101A (en) 2000-08-08 2002-02-18 Ortho Mcneil Pharm Inc Non-imidazole aryloxypiperidines
PT1311499E (pt) 2000-08-08 2006-07-31 Ortho Mcneil Pharm Inc Compostos biciclicos como ligandos do receptor h3
JP2005502623A (ja) 2001-07-02 2005-01-27 ノボ　ノルディスク　アクティーゼルスカブ 置換ピペラジンおよびジアゼパン
US7208497B2 (en) 2001-07-02 2007-04-24 Novo Nordisk A/S Substituted piperazines and diazepanes
US20030186963A1 (en) 2001-09-14 2003-10-02 Dorwald Florencio Zaragoza Substituted piperidines
US6673829B2 (en) 2001-09-14 2004-01-06 Novo Nordisk A/S Aminoazetidine,-pyrrolidine and -piperidine derivatives
EP1434765B1 (en) * 2001-09-14 2009-12-02 High Point Pharmaceuticals, LLC Substituted piperidines with selective binding to histamine h3-receptor
WO2003024928A2 (en) 2001-09-14 2003-03-27 Novo Nordisk A/S Novel aminoazetidine, -pyrrolidine and -piperidine derivatives
EP1444219A1 (en) 2001-10-12 2004-08-11 Novo Nordisk A/S Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor
US7064135B2 (en) 2001-10-12 2006-06-20 Novo Nordisk Inc. Substituted piperidines
JP2005511764A (ja) 2001-12-14 2005-04-28 アルコン，インコーポレイテッド 緑内障の処置のためのアミノアルキルベンゾフラン−５−オール化合物
US20030236259A1 (en) * 2002-02-05 2003-12-25 Rolf Hohlweg Novel aryl- and heteroarylpiperazines
GB0211230D0 (en) * 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
US7332508B2 (en) 2002-12-18 2008-02-19 Novo Nordisk A/S Substituted homopiperidine, piperidine or pyrrolidine derivatives
GB0325956D0 (en) * 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
BRPI0512046A (pt) 2004-06-15 2008-02-06 Pfizer derivados de ácido benzimidazolona carboxìlico
US7737163B2 (en) 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
MX2007015675A (es) 2005-07-04 2008-02-20 Novo Nordisk As Antagonistas del receptor de histamina h3.
CN101321525B (zh) * 2005-12-01 2013-01-30 霍夫曼-拉罗奇有限公司 作为l-cpt1抑制剂的杂芳基取代的哌啶衍生物
KR20090040259A (ko) 2006-05-29 2009-04-23 하이 포인트 파마슈티칼스, 엘엘씨 3-(1,3-벤조디옥솔-5-일)-6-(4-시클로프로필피페라진-1-일)-피리다진, 그것의 염과 용매화합물 및 그것의 히스타민 ｈ3 수용체 안타고니스트로서의 용도
EP2014656A3 (en) 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC New heteocyclic h3 antagonists
ME02107B (me) 2011-09-19 2015-10-20 Heteroaril jedinjenja kao ligandi 5-ht4 receptora

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055476A (en) * 1990-08-13 1991-10-08 Hoechst-Roussel Pharmaceuticals Incorporated 3-(1,2-benzisoxazol-3-yl)-4-pyridinamines and derivatives
AU2435092A (en) * 1991-08-20 1993-03-16 Smithkline Beecham Plc 5-ht4 receptor antagonists
FI941178L (fi) * 1991-09-12 1994-03-11 Smithkline Beecham Plc 5-HT4-reseptoriantagonisteja
NZ246915A (en) * 1992-02-06 1996-05-28 Smithkline Beecham Plc Benzopyran, benzothiopyran and benzofuran derivatives, preparation and pharmaceutical compositions thereof
GB9219163D0 (en) * 1992-09-10 1992-10-28 Smithkline Beecham Plc Pharmaceuticals
JPH06157518A (ja) * 1992-11-27 1994-06-03 Yamanouchi Pharmaceut Co Ltd 新規なオキサジアゾール誘導体又はその塩

Also Published As

Publication number Publication date
BG102412A (en) 1999-08-31
ATE181328T1 (de) 1999-07-15
NO982092L (no) 1998-06-29
AU7500196A (en) 1997-05-29
CZ142198A3 (cs) 1998-08-12
MX9803696A (es) 1998-09-30
AU707325B2 (en) 1999-07-08
GR3030823T3 (en) 1999-11-30
AR004708A1 (es) 1999-03-10
CN1077891C (zh) 2002-01-16
CN1202169A (zh) 1998-12-16
NO309606B1 (no) 2001-02-26
US5929089A (en) 1999-07-27
UA50748C2 (uk) 2002-11-15
TR199800827T2 (xx) 1999-02-22
HUP0001168A3 (en) 2001-07-30
CA2236357C (en) 2006-10-17
DE69602970T2 (de) 2000-01-20
PL186204B1 (pl) 2003-11-28
ES2135934T3 (es) 1999-11-01
PL326671A1 (en) 1998-10-12
EP0863897B1 (fr) 1999-06-16
NO982092D0 (no) 1998-05-07
BG63463B1 (bg) 2002-02-28
DE69602970D1 (de) 1999-07-22
CA2236357A1 (en) 1997-05-15
SK282335B6 (sk) 2002-01-07
EE03487B1 (et) 2001-08-15
SK59998A3 (en) 1998-11-04
IL124364A0 (en) 1998-12-06
RU2167160C2 (ru) 2001-05-20
CZ287268B6 (en) 2000-10-11
CO4770968A1 (es) 1999-04-30
HUP0001168A2 (hu) 2001-04-28
EE9800155A (et) 1998-12-15
SI0863897T1 (en) 1999-10-31
JP2000500125A (ja) 2000-01-11
WO1997017345A1 (fr) 1997-05-15
BR9611311A (pt) 1999-06-29
EP0863897A1 (fr) 1998-09-16
JP4263240B2 (ja) 2009-05-13
HK1016165A1 (en) 1999-10-29
IL124364A (en) 2001-08-08
TW371303B (en) 1999-10-01

Similar Documents

Publication Publication Date Title
NZ321626A (en) 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h)-one derivatives for use as 5-ht4 or h3 receptor ligands
HUP9901115A3 (en) Indole derivatives as 5-ht receptor antagonist
HUP0003425A3 (en) 2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-1h-indole derivatives and pharmaceutical compositions containing the compounds
FR2637796B1 (fr) Charniere pour abattant de w.c.
IL132352A0 (en) 5-Aryl-3-(8-azabicyclo (3.2.2) oct-3yl) -1,3,4-oxadiazol 22 (3h) - one derivatives as 5-ht4 receptor ligands
IL108784A0 (en) Use of 2h-1,2,4-benzothiadiazin-3(4h)-one 1,1-dioxide derivatives as noncompetitive antagonists of the mmda receptor
GB9704376D0 (en) Tetrahydropyridine derivatives as dopamine receptor subtype ligands
HUP9600333A2 (en) Azole derivatives as adhesive receptor antagonists, pharmaceutical compositions containing the same and process for their preparation
PL326630A1 (en) Methods of obtaining 3-(1-piperasinyl)-1,2-benzoisothiazole and novel initial compounds therefor
ZA95306B (en) 3-aryl-alkenyl-1,2,4-oxadiazole derivatives
DK0863897T3 (da) Derivater af 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3H)-on, som kan anvendes som ligander for 5-HT4- eller H3-recept
NZ300041A (en) 2-(2,3,5,6-tetrafluoropyridin-4-yl)-1,2,5-thiazolidin-3-one 1,1-dioxide derivatives
AU7658798A (en) 5-phenyl-1,3,4-oxadiazol-2(3h)-one derivatives and their use as 5-ht4 ligands
AU7658898A (en) 3-(pyrrolidin-3-yl)-1,3,4-oxadiazol-2(3h)-one derivatives and their use as 5-ht4ligands
HUP9801716A3 (en) 5h,10h-imidazo[1,2-a]indeno[1,2-e]pyrazin-4-one derivatives, ph
ZA969418B (en) 5-Phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol 2(3H)-one derivatives their preparation and their application in therapeutics
AU4319797A (en) 2-(3-piperidyl)-1,2,3,4-tetrahydroisoquinoline derivatives or medicinal compositions thereof
FR2741069B1 (fr) Derives de 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h) -one, leur preparation et leur application en therapeutique
FR2745574B1 (fr) Derives de 5-phenyl-3-(piperidin-4-yl)-1, 3, 4-oxadiazol-2 (3h)-one, leur preparation et leur application en therapeutique
HU9503566D0 (en) Hygenic part for wc seat
FR2759699B1 (fr) Derives de 5-(2,3-dihydro-1,4-benzoxazin-5-yl)-3-(piperidin- 4-yl)-1,3,4-oxadiazol-2(3h)-one, leur preparation et leur application en therapeutique
SI1019385T1 (en) Aminoaryl oxazolidinone n-oxides
TW332514U (en) Adjustable lock seat

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired